Politiparty
Politiparty
LeaderboardCongressBills

119th Congress Health

H.R. 8205: Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026

Passed CongressSep 28, 2026

  1. Introduced (completed)Apr 6, 2026
  2. Passed House (completed)Jul 22, 2026
  3. Passed Senate (completed)Sep 28, 2026
  4. To the President (not reached)
  5. Became law (not reached)

Summary

Reported to House, Jul 9, 2026

This bill reauthorizes through FY2031 and revises programs that support research and development of drugs and other therapies to address amyotrophic lateral sclerosis (also known as ALS or Lou Gehrig's disease) and other neurodegenerative diseases.

The bill reauthorizes

  • grants from the National Institutes of Health (NIH) for scientific research on investigational drugs to prevent or treat ALS for individuals not otherwise eligible for clinical trials,
  • grants from the Food and Drug Administration (FDA) for research and development of therapies to prevent and treat ALS and other neurodegenerative diseases, and
  • a Public-Private Partnership including the FDA and NIH that supports development and regulatory review of treatments for neurodegenerative diseases.
Read the full summary

Also, the NIH, in considering renewal of its grants, must assess available information on the safety and efficacy of the investigational drugs. It must also require grantees to promptly report serious and unexpected adverse events associated with their investigational drugs.

Additionally, the FDA must publish a plan describing actions it will take over a five-year period to foster development of safe and effective drugs, and facilitate access to investigational drugs, that treat ALS and other rare neurodegenerative diseases. The FDA must also publish a report describing the actions it has taken under the plan.

Written by the Congressional Research Service, Library of Congress.

Roll calls

0 votes on this bill

No roll call votes have been held on this bill.

Amendments

0 offered

No amendments were offered to this bill.

Cosponsors

103

Bipartisan support.

Who scored on this bill

538 points earned
  1. 1Mike Quigley D-IL SponsorDrew cross-party cosponsors, introduced, reached a cosponsor milestone, marked up, reported, passed House, passed Senate9 events+126
  2. 2Alma Adams D-NCCosponsored; cosponsored bill passed2 events+4
  3. 2Robert Aderholt R-ALCosponsored; cosponsored bill passed2 events+4
  4. 2Mark Alford R-MOCosponsored; cosponsored bill passed2 events+4
  5. 2Mark Amodei R-NVCosponsored; cosponsored bill passed2 events+4
See all scorers and every scoring event

Introductions and cosponsorships count toward weekly caps and show no points.

Other bills by Mike Quigley

History

  1. Sep 28, 2026Passed the Senate by voice vote.
  2. Jul 22, 2026Passed the House by voice vote.
  3. Apr 6, 2026Introduced in the House by Mike Quigley.
Show the full action history (24 actions)
  1. Oct 14, 2026Message on Senate action sent to the House.
  2. Sep 28, 2026Passed/agreed to in Senate: Passed Senate without amendment by Voice Vote. (consideration: CR S5120)
  3. Sep 28, 2026Passed/agreed to in Senate: Passed Senate without amendment by Voice Vote.
  4. Sep 28, 2026Passed Senate without amendment by Voice Vote. (consideration: CR S5120)
  5. Jul 23, 2026Received in the Senate. Read twice. Placed on Senate Legislative Calendar under General Orders. Calendar No. 466.
  6. Jul 22, 2026Considered as unfinished business. (consideration: CR H5159)
  7. Jul 22, 2026Considered as unfinished business.
  8. Jul 22, 2026Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.
  9. Jul 22, 2026On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.
  10. Jul 22, 2026Motion to reconsider laid on the table Agreed to without objection.
  11. Jul 20, 2026Considered under suspension of the rules. (consideration: CR H4652-4654; text: CR H4653)
  12. Jul 20, 2026Mr. Guthrie moved to suspend the rules and pass the bill, as amended.
  13. Jul 20, 2026Considered under suspension of the rules.
  14. Jul 20, 2026DEBATE - The House proceeded with forty minutes of debate on H.R. 8205.
  15. Jul 20, 2026At the conclusion of debate, the chair put the question on the motion to suspend the rules. Mr. Guthrie objected to the vote on the grounds that a quorum was not present. Further proceedings on the motion were postponed. The point of no quorum was considered as withdrawn.
  16. Jul 9, 2026Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 119-733.
  17. Jul 9, 2026Placed on the Union Calendar, Calendar No. 637.
  18. May 21, 2026Committee Consideration and Mark-up Session Held
  19. May 21, 2026Ordered to be Reported (Amended) by the Yeas and Nays: 46 - 0.
  20. May 13, 2026Subcommittee Consideration and Mark-up Session Held
  21. May 13, 2026Forwarded by Subcommittee to Full Committee by Voice Vote.
  22. Apr 6, 2026Introduced in House
  23. Apr 6, 2026Referred to the House Committee on Energy and Commerce.
  24. Apr 6, 2026Referred to the Subcommittee on Health.